etoposide IV / Generic mfg. - LARVOL DELTA

Update AML: Updated disease monitoring and treatment to enhance outcomes for pediatric AML (NCT07059975) (ASH 2025) - P1 | "These patients will receive the common salvage regimen Idarubicin-fludarabine-cytarabine (IdaFLA) as the second cycle (Induction 2) in lieu of standard DA8 (Daunorubicin-Cytarabine) chemotherapy...In UPDATE AML, IR patients will receive VIA in place of MA (mitoxantrone-cytarabine) to eliminate exposure to the cardiotoxic agent mitoxantrone. HR patients will receive VIA as Intensification 1 prior to SCT, in place of the genotoxic agent etoposide and to provide venetoclax exposure prior to SCT...All newly diagnosed patients at TXCH >1 month to <30 years old with non-FLT3-ITD+ AML will be eligible for enrollment after completing standard Induction 1 chemotherapy consisting of combination of daunorubicin and cytarabine +/- gemtuzumab...Over 3 years, the study is anticipated to accrue 36-40 patients and generate important feasibility data for our treatment and molecular MRD innovations. Our results will inform future cooperative group trials with respect to..."

Clinical • IO biomarker • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Pediatrics • FLT3

Venetoclax-based salvage therapy achieves high remission rates after 7+3 or low-dose cytarabine (ASH 2025) - "Introduction: In the Brazilian public health system (SUS), salvage chemotherapy for fit patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) after standard 7+3 induction (7 days of cytarabine plus 3 days of an anthracycline) is usually FLAG-IDA (fludarabine, cytarabine, granulocyte colony-stimulating factor [G-CSF], and idarubicin) or MEC (mitoxantrone, etoposide, and cytarabine)...Although the venetoclax–cytarabine (VEN-ARAC) or venetoclax–azacitidine (VEN-AZA) combination is approved as first-line therapy for unfit patients, it is generally not available in SUS... In this real-world study, VEN-based salvage therapy induced rapid and high CR rates after 7+3 or LDAC, with a favorable safety profile, and may serve as a less-toxic bridge to allo-HSCT."

Clinical • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Neutropenia

Real-world AML survival paradox: Early escalation vs. sustained remission (ASH 2025) - "Patients were stratified into two cohorts: Cohort A (early escalation, n=1,460), comprising patients who received either second-line chemotherapy (including fludarabine, cladribine, gilteritinib, enasidinib, revumenib, olutasidenib, etoposide, or clofarabine) or hematopoietic stem cell transplant (HSCT) as salvage therapy within 6 months of completing initial therapy; and Cohort B (no escalation, n=10,540), consisting of patients who received no additional therapy during this same period. Our findings highlight the complex interplay between disease biology and treatment interventions: achieving MRD-negativity remains critical, but when MRD-positivity occurs, subsequent treatment decisions based on disease genetics prove critical. Prospective studies incorporating molecular MRD monitoring are needed to confirm these findings and further optimize post-remission therapy approaches."

Clinical • Real-world • Real-world evidence • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia

Vincristine-induced neuropathy: Long term follow-up of lymphoma survivors treated with CHOP or dose-adjusted EPOCH chemotherapy (ASH 2025) - "Introduction: The incidence of Vincristine-induced neuropathy (VIN) occurs in up to 70% of non Hodgkin Lymphoma (NHL) survivors treated with front-line lymphoma regimens such as CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) and infusional dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin), administered with or without rituximab (R) (Su et al., 2025). Overall, neuropathy outcomes varied in our cohort. For most, CIPN20 scores were stable to improved between T3 and T4, yet 3 participants (mean age 68.7) reported persistent numbness and tingling in their feet and toes. Increasing age has been reported as a risk factor for development of chemotherapy induced neuropathy with one study reporting persistence of symptoms in the post-treatment phase (Bulls et al., 2019; Hershman et al., 2016)."

Constipation • Gastroenterology • Gastrointestinal Disorder • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Pain

Real-world characteristics and outcomes of patients with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) who received second line therapy, stratified by stem cell transplant status (ASH 2025) - "Gemcitabine-oxaliplatin plus rituximab (R-GemOx) is a common regimen that is well-tolerated in older adults with other comorbidities, for whom treatment of DLBCL is challenging and has inferior outcomes...The most common 2L treatment regimens were rituximab, ifosfamide, carboplatin, plus etoposide in ASCT (n=41, 62.1%) and bendamustine plus rituximab (n=62, 18.6%) in non-ASCT treated groups...A higher percentage of patients in the non-ASCT treated group, specifically in the R-GemOx subgroup, were older with higher ECOG scores and inferior treatment related outcomes, including a minority alive at 2 years. These findings highlight a continuing unmet need for more effective, safer treatments for patients with R/R DLBCL ineligible for or unable to access ASCT or CAR-T."

Clinical • Real-world • Real-world evidence • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Transplantation

Long-term HIV remission of a perinatally infected individual, following a hematopoietic cell transplantation from a CCR5Δ32 homozygous donor for multiple myeloma: The kyiv patient (ASH 2025) - "Complete remission (CR) was achieved after one cycle of melphalan/prednisone and local radiotherapy, but an abdominal relapse occurred six months later. Despite subsequent lines of therapy (bortezomib(bort)/lenalidomide(lena)/dexamethasone(dexa) and bendamustine/bort/dexa), the extramedullary multiple myeloma (MM) progressed. Remission was achieved after dexa/thalidomide/cisplatin/doxorubicin/cyclophosphamide/etoposide (DT-PACE) and an autologous HCT performed on 1/2021...Allogeneic HCT was performed in 8/2022 after fludarabine/melphalan conditioning and anti-thymocyte globulin from a CCR5-Δ32homozygous, unrelated HLA-matched donor; cyclosporine/methotrexate was utilized as graft-versus-host diseas e (GVHD) prophylaxis... To our knowledge, this represents the first report of ART-free HIV RNA suppression following allogeneic HCT with a CCR5Δ32homozygous donor in an individual perinatally infected with HIV. Despite the differences in the latent reservoir and the mechanism..."

Clinical • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Human Immunodeficiency Virus • Immunology • Infectious Disease • Multiple Myeloma • Plasmacytoma • Transplantation • CCR5 • CD4 • CD8

Diluting high yield hematopoietic stem cell apheresis for autologous transplantation results in high viability of fresh grafts beyond 72h (ASH 2025) - "At the Instituto de Prevision Social all lymphoma patients are transplanted with fresh grafts using a shortened BEAM protocol with time to collect to infusion of 96 hours (BCNU d-4; Ara-C d-4, d-3, d-2; Etoposide d-4, d-3, d-2; Melphalan d-2) and minimum CD34+ cells of 2,5 x 10*6...All patients were mobilized with GCSF +/- Plerixafor... While this is a very limited study due to number of participants, its retrospective nature and single center experience the data suggests diluting high yield apheresis products result in high viability of HPSC beyond 72 hours. Any HCT Program should aim to have cryopreservation facilities available as there are some patients that cannot be transplanted safely without said capacities. However, this may not be the case for Lymphoma patients."

Hematological Malignancies • Immunology • Lymphoma • Multiple Myeloma • Solid Tumor • Transplantation • CD34

Etoposide +cytarabine plus G-CSF mitigates daratumumab-associated impairment on stem cell mobilization yields in multiple myeloma (ASH 2025) - "Objective: Quadruplet induction therapy comprising daratumumab(dara) and lenalidomide(lena), followed by high-dose chemotherapy and autologous stem cell transplantation (ASCT) has become the standard frontline treatment for patient with multiple myeloma(MM). The median total CD34+ cells collection was 19.33 × 10⁶/kg in the dara group, significantly lower than that in lena group (25.59 × 10⁶/kg, p=0.005). Notably, patients receiving more than eight doses of dara showed a reduced CD34+ cell collection (median 14.16 × 10⁶/kg vs. 21.45 × 10⁶/kg; p = 0.039)."

Hematological Disorders • Hematological Malignancies • Lymphoma • Multiple Myeloma • Neutropenia • CD34

Dara-RVD in newly diagnosed multiple myeloma: Real-world clinical practice (ASH 2025) - "Depending on post-ASCT MRD status, patients received lenalidomide maintenance therapy, if MRD negativity was achieved...Antitumor treatment was administered alongside supportive therapy (sulfamethoxazole-trimethoprim, acyclovir), immunoglobulin infusions, osteomodifying agents...Seven patients underwent stem cell harvesting (etoposide 750 mg/m 2 )combined with short-acting filgrastim without routine plerixafor administration...Conclusion : In the context of limited access to CAR T-cell and bispecific therapies in Russia, early use of Dara-RVd with MRD-adaptive strategies shows high efficacy, including high-risk NDMM patients. This quadruplet-based approach may shift the treatment paradigm, though careful monitoring for complications like hypogammaglobulinemia is essential."

Clinical • Real-world • Real-world evidence • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Musculoskeletal Pain • Pneumococcal Infections • Renal Disease • Respiratory Diseases • CD34 • CTCs

Isa-PACE in the treatment of functionally high-risk multiple myeloma: Intermediate results. (ASH 2025) - "In the absence of chimeric antigen receptor T-cell (CAR-T) therapy in Russia, the Isa-PACE (isatuximab + cisplatin, doxorubicin, cyclophosphamide, and etoposide) combination is considered a potential bridge therapy to auto-HSCT...All patients continue to receive maintenance therapy with isatuximab and lenalidomide, while maintaining MRD-negative status...Intermediate assessment of PET/CT imaging effectively reflected the response to treatment and identified the need for treatment intensification. Expanding the sample size will help to clarify the prognostic significance of this approach and aid in stratifying patients with NDMM."

Bone Marrow Transplantation • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Human Papillomavirus Infection • Infectious Disease • Multiple Myeloma • Neutropenia • Plasmacytoma • Thrombocytopenia

Outcomes of infusional chemotherapy regimens in multiple myeloma: A retrospective review at a single center from 2018 to 2025 (ASH 2025) - "Despite emergence of novel agents, the use of traditional multi-agent infusional regimens such as DCEP (dexamethasone, cyclophosphamide, etoposide, cisplatin) and V(T)D-PACE (bortezomib, thalidomide, dexamethasone, cisplatin, doxorubicin, cyclophosphamide, etoposide) remain critical in select clinical scenarios. These regimens continue to be valuable in providing rapid cytoreduction or as a bridge to definitive therapy. Larger sample sizes are required in order to perform statistical analysis on subgroups to better characterize differences in therapy with respect to progression free survival, overall response rate, and time to response."

Retrospective data • Review • Hematological Malignancies • Leukemia • Multiple Myeloma • Plasma Cell Leukemia

Real-world outcomes of glofitamab-based regimens in relapsed/refractory aggressive B-cell lymphoma (ASH 2025) - "Introduction: Glofitamab, a bispecific antibody targeting CD20 and CD3, is approved for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) following at least one prior line of therapy, either as monotherapy or in combination with gemcitabine and oxaliplatin (GemOx)...Specifically, 6 patients (17.1%) had a history of bendamustine exposure, and 4 patients (11.4%) had undergone both autologous stem cell transplantation and chimeric antigen receptor T-cell therapy...Among them, the regimens included glofitamab monotherapy (28, 80.0%), glofitamab combination with bruton tyrosine kinase inhibitors (3, 8.6%), GemOx (2, 5.7%), polatuzumab vedotin (1, 2.9%) or dose-reduced ifosfamide, carboplatin and etoposide (1, 2.9%)... Our findings characterize disease features of heavily treated r/r aggressive B-cell lymphoma and real-world outcomes with glofitamab-based salvage. Even in the subgroups with adverse prognosis factors, glofitamab-based regimens still demonstrated..."

Clinical • Real-world • Real-world evidence • B Cell Lymphoma • Burkitt Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Leukopenia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • CD4 • TP53

Epcoritamab monotherapy provides superior efficacy vs non–anthracycline-containing regimens in newly diagnosed elderly DLBCL patients deemed unsuitable for anthracycline-containing regimens: A match-adjusted comparative efficacy analysis (ASH 2025) - P2 | "Non-AC CITs included rituximab (R)-cyclophosphamide, doxorubicin, vincristine, prednisone [R-CEOP]/R-cyclophosphamide, vincristine, prednisone [R-CVP]/R-cyclophosphamide, etoposide, prednisone, procarbazine [R-CEPP]), bendamustine and rituximab (BR), and other combination regimens. Fixed-duration epcor mono demonstrated significantly superior OS vs non-AC regimens in newly diagnosed elderly and/or frail DLBCL pts deemed unsuitable for anthracyclines. These findings support epcor mono as a potential 1L chemo-free treatment option for newly diagnosed DLBCL pts unsuitable for AC regimens."

Clinical • Monotherapy • Diffuse Large B Cell Lymphoma • Large B Cell Lymphoma • Palliative care

Ruxolitinib in malignancy-associated hemophagocytic lymphohistiocytosis (M-HLH): A systematic literature review (ASH 2025) - P1/2, P4 | "Comparison of R-DED regimen (Ruxolitinib 0.3 mg/kg/day(Day1–14) + doxorubicin(20mg Day1–2) + etoposide(100mg Day1, 50mg Day2–5) + dexamethasone(10mg BID Day1–5, then 10mg OD Day6–14) with HLH-94 therapy achieved an ORR of 89%(CR:50%, PR:39%), with a median OS of 5.4 months as compared to 1.5 months in the control group. Ruxolitinib shows promise as a targeted therapy for malignancy-associated HLH, achieving response rates up to 100% with manageable toxicity in early-phase studies. Early and timely incorporation of ruxolitinib with rapid bridge to definitive therapy needs to be studied due to very high 28 day mortality in LAHS. Larger prospective trials are urgently needed to validate efficacy, optimize dosing strategies, and define its role within current HLH treatment paradigms."

Review • Febrile Neutropenia • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Immunology • Infectious Disease • Lymphoma • Neutropenia • Oncology • Rare Diseases

Efficacy and safety of pola-ICE, with or without rituximab in relapsed/refractory diffuse large B-cell lymphoma: A real-world multicenter study (ASH 2025) - "Polatuzumab vedotin (Pola), an antibody-drug conjugate targeting CD79b, has demonstrated safety and efficacy when combined with bendamustine and rituximab in transplant-ineligible patients (pts) with relapsed DLBCL pts. We evaluated the safety and efficacy of Pola-ICE regimen—comprising polatuzumab vedotin, ifosfamide, carboplatin, and etoposide—with or without the addition of rituximab in R/R DLBCL pts in the real world...All patients received Pola-ICE: Pola 1.8 mg/kg (day 1), ifosfamide 4000 mg/m² (administered in two divided doses, days 1–2, with MESNA infusion), carboplatin AUC 4 (day 2), etoposide 100 mg/m² (days 1–3), repeated every 21 days up to 6 cycles... Pola-ICE, with or without rituximab, demonstrated promising efficacy with high-quality responses and manageable toxicity in heavily pretreated R/R DLBCL pts. This salvage regimen may serve as a viable option for high-risk patients, potentially enabling subsequent curative-intent therapies."

Clinical • Real-world • Real-world evidence • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Thrombocytopenia • CD79B

A tale of two lymphomas: A rare case of transformative post-transplant lymphoproliferative disorder (ASH 2025) - "Our 61-year-old patient underwent a living-unrelated renal transplant in 2014 for focal segmental glomerulosclerosis and was maintained on mycophenolate mofetil (MMF) and cyclosporine (CsA)...MMF was discontinued, and he received four weekly doses of rituximab (375 mg/m²), achieving complete remission (CR) and was consolidated with four additional Rituximab doses by Jan 2024...After improvement of liver and kidney function, therapy was escalated to brentuximab vedotin (BV) with cyclophosphamide, doxorubicin, and prednisone (CHP), given his CD30 expression...After detailed goals-of-care discussions, he and the care team elected to proceed with additional therapy with EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin), since he already received azacitidine, romidepsin, and BV-CHP...His care underscores the importance of multidisciplinary collaboration, patient-centered decision-making, and longitudinal follow-up. He has been referred to our..."

Clinical • IO biomarker • Post-transplantation • Bone Marrow Transplantation • Chronic Kidney Disease • Epstein-Barr Virus Infections • Febrile Neutropenia • Focal Segmental Glomerulosclerosis • Follicular Lymphoma • Glomerulonephritis • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Hepatology • Immunology • Infectious Disease • Liver Failure • Lymphoma • Nephrology • Peripheral T-cell Lymphoma • Rare Diseases • T Cell Non-Hodgkin Lymphoma • Transplantation • BCL6 • CD21 • CD4 • CD5 • CD7 • ICOS • JAK1 • PD-1 • RHOA • TET2 • TNFRSF8

Mitoxantrone liposome combined with EAC autologous transplant conditioning for the treatment of T/NK non-Hodgkin's lymphoma (ASH 2025) - " The study retrospectively analyzed the data of T/NK cell lymphoma patients who underwent autologous hematopoietic stem cell transplantation from January 2023 to December 2024 in Xinqiao Hospital of the Army Medical University, and the transplant pretreatment regimen was: intravenous infusion of mitoxantrone hydrochloride liposomal 24mg/m 2 on the 7th day before autologous stem cell reinfusion; Etoposide 150 mg/m 2 daily from day 6 to day 3 before reinfusion; Cytarabine 150 mg/m 2 2 times/day from day 6 to day 3 before reinfusion; Cyclophosphamide 1.0 g/m 2 daily from day 6 to day 3 before reinfusion. Mitoxantrone liposomes combined with EAC conditioning for transplantation of T/NK non-Hodgkin lymphoma are safe and effective, and well tolerated, and the implantation kinetics have not changed, but further follow-up and expanded sample size evaluation are needed."

Bone Marrow Transplantation • Extranodal Natural Killer/T-cell Lymphoma • Febrile Neutropenia • Lymphoma • Natural Killer/T-cell Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • T Cell Non-Hodgkin Lymphoma • Transplantation

Navigating classical Hodgkin lymphoma in a patient with DIAPH1 deletion syndrome: Diagnostic and therapeutic challenges in a rare immuno-genetic context (ASH 2025) - P | "He was commenced on full dose OEPA (vincristine, etoposide, prednisolone, doxorubicin) after histopathologic confirmation of cHL, and following 2 cycles his early response assessment PET showed complete metabolic response. Due to concerns about hepatic enzyme induction and mitochondrial toxicity, anti-seizure therapy was changed to levetiracetam and clobazam, as carbamazepine is a potent CYP3A4 inducer that may decrease exposure to drugs like methylprednisolone (Bartoszek et al., 1987)...This is the first report showing feasibility of full dose induction therapy for cHL with intensive supportive care in DIAPH1 deficiency. Nonetheless, ongoing careful individualised dosing, vigilant toxicity monitoring, and multidisciplinary input remain essential."

Clinical • B Cell Lymphoma • Classical Hodgkin Lymphoma • CNS Disorders • Dental Disorders • Developmental Disorders • Diffuse Large B Cell Lymphoma • Epilepsy • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Mental Retardation • Mucositis • Neutropenia • Non-Hodgkin’s Lymphoma • Ophthalmology • Stomatitis • CYP3A4

Experience with prolgolimab in the treatment of patients with relapsed and refractory classical Hodgkin lymphoma (ASH 2025) - "Objective: To evaluate the efficacy and safety of prolgolimab both as monotherapy and in combination with DHAP chemotherapy (dexamethasone, cytarabine, cisplatin), as well as to assess the feasibility of peripheral blood stem cell (PBSC) collection followed by auto-HSCT in patients with r/r cHL...Disease progression was noted in 6 patients, who were subsequently switched to bendamustine-based chemotherapy regimens. PBSC collection was successfully performed in 15 patients after chemomobilization with etoposide (375 mg/m²/day on days 1–2)... The combination of prolgolimab with DHAP chemotherapy is highly effective and safe, with no negative impact on PBSC collection. Achieving tumor response prior to auto-HSCT and the use of prolgolimab as consolidation therapy can lead to durable remissions without additional toxicity in patients with r/r cHL."

Clinical • Bone Marrow Transplantation • Cardiovascular • Classical Hodgkin Lymphoma • Endocrine Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Pulmonary Embolism • Respiratory Diseases • CD34 • PD-L2

Checkpoint inhibitors improve progression free survival after autologous transplant despite poorer pre-transplant response (ASH 2025) - "Introduction The checkpoint inhibitors (CI) nivolumab and pembrolizumab which target PD1 are established treatments for relapsed/refractory classic Hodgkin Lymphoma (cHL)...44 received brentuximab vedotin (BV)...All patients were conditioned with LEAM (lomustine, etoposide, cytarabine, melphalan)...CI treatment prior to ASCT may alter cHL disease biology leading to increased sensitization to subsequent high dose cytotoxic chemotherapy although more exploratory data assessing the mechanism is needed. We are planning a multi-centre analysis to investigate further."

Checkpoint inhibition • Pre-transplantation • Cardiovascular • Classical Hodgkin Lymphoma • Diabetes • Gastroenterology • Gastrointestinal Disorder • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Lymphoma • Metabolic Disorders • Oncology • Pneumonia • Transplantation

A diagnostic pitfall: Therapy-related acute promyelocytic leukemia mimicking mixed-phenotype acute leukemia (ASH 2025) - "The BC was treated according to national guidelines with surgery, radiation therapy, chemotherapy (4 cycles of etoposide and cyclophosphamide and 12 cycles of paclitaxel), and endocrine maintenance therapy and has been in remission ever since...Induction therapy was immediately initiated according to the current APL treatment standard with tretinoin (ATRA) and arsenic trioxide (ATO) plus a single dose of idarubicin based on the APOLLO study for cytoreduction because the patient developed hyperleukocytosis mainly due to administration of corticosteroids...(II.) Even in the context of previous chemotherapy, genetic testing is mandatory as t-APL is treated specifically and shows a better prognosis than other forms of therapy-related AML. (III.) It highlights the importance of careful integrated diagnostics for acute leukemias that incorporate morphology, flow cytometry, and genetic results to guide therapeutic decision-making."

Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Acute Promyelocytic Leukemia • Breast Cancer • Gene Therapies • Hematological Malignancies • Leukemia • Solid Tumor

Hodgkin lymphoma in a patient with Hemophilia A on emicizumab prophylaxis: A case report (ASH 2025) - "He completed five cycles of chemotherapy with brentuximab, doxorubicin, etoposide, prednisone, cyclophosphamide and vincristine. As emicizumab is intended for long term maintenance therapy, it is critical to report any significant adverse events. This case further suggests that continued use of emicizumab during cancer-directed therapies is safe and effective for patients with hemophilia A."

Case report • Clinical • Classical Hodgkin Lymphoma • Hematological Malignancies • Hemophilia • Hemophilia A • Hemophilia B • Hodgkin Lymphoma • Human Immunodeficiency Virus • Infectious Disease • Lymphoma • Rare Diseases • Thrombocytopenia

Anakinra for hemophagocytic lymphohistiocytosis: A real-world, multicenter retrospective study on efficacy, safety, and response durability (ASH 2025) - "Current standard etoposide-based chemotherapy regimens can control the disease, but their significant toxicities limit clinical use, especially in patients with poorer fitness or contraindications, so there is an urgent clinical need for safer, more rapidly-acting targeted treatment options. Anakinra can rapidly control disease progression and significantly reduce steroid use in real-world treatment of HLH, demonstrating good short-term efficacy. However, the duration of remission is short, suggesting that combination therapy or prolonged use may be necessary to consolidate efficacy. Although the sample size is limited and the study is retrospective, this research provides important reference for the clinical application of Anakinra in the treatment of HLH."

Real-world • Real-world evidence • Retrospective data • Hemophagocytic lymphohistiocytosis • Immunology • Inflammation • Rare Diseases

Diagnostic challenges in adult hemophagocytic lymphohistiocytosis: A case series (ASH 2025) - "Quickly identifying the condition, using clinical tools like the HScore, and starting immunosuppressive therapy (such as dexamethasone and etoposide) early are vital for better survival rates. Strong clinical suspicion, prompt diagnostic tests, and swift treatment actions are key strategies to address the negative outcomes related to delayed diagnosis in adult HLH."

Clinical • Bone Marrow Transplantation • Febrile Neutropenia • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Hodgkin Lymphoma • Immunology • Infectious Disease • Lymphoma • Rare Diseases • Respiratory Diseases

Adult-onset hemophagocytic lymphohistiocytosis triggered by sars-cov-2 and EBV coinfection: A diagnostic challenge resolved with the HLH-94 protocol (ASH 2025) - "A multidisciplinary team including hematology, infectious disease, and ICU started HLH-directed therapy per HLH-94 protocol: dexamethasone (10 mg/m²/day) and etoposide...While our patient responded to HLH-94 induction alone, ruxolitinib may represent a valuable adjunct in future cases, especially in virally driven hyperinflammatory states. Conclusion Adult HLH should be considered in patients with persistent fevers, cytopenias, and hyperferritinemia unresponsive to standard infection management. This case demonstrates how timely diagnosis and early implementation of the HLH-94 protocol, in collaboration with a multidisciplinary team, can reverse multiorgan failure in high-mortality syndromes like HLH."

Clinical • Epstein-Barr Virus Infections • Hematological Disorders • Hemophagocytic lymphohistiocytosis • Hypotension • Immunology • Infectious Disease • Novel Coronavirus Disease • Rare Diseases • Respiratory Diseases • Septic Shock • IL2